With its lead antibiotic under a cloud, Cempra asks Morgan Stanley for help with a strategic review
With its stock price beaten down by successive setbacks for its lead antibiotic, Cempra has brought in Morgan Stanley to help advise its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
